FAGOTTO study

INTERVENTION: am A ; CANAGLU tablet 100mg /day am B ; control CONDITION: D003924 Diabetes Mellitus, Type 2 ; Diabetes Mellitus, Type 2 PRIMARY OUTCOME: Rate of change in FF (filtration fraction) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group SECONDARY OUTCOME: ‐Change in FF after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group; ‐Rate of change and change in Cin (glomerular filtration rate by inulin) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group; ‐Rate of change and change in RPR (renal plasma flow) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group; ‐Rate of change and change in RBR (renal blood flow) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group; ‐Rate of change and change in RVR (renal vascular resistance) after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group; ‐Change in eGFR, HbA1c and albuminuria (proteinuria) after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group; ‐Change in blood pressure and body weight after 4 and 12 weeks of treatment relative to the baseline between canagliflozin intervention group and control group ; ‐Change in urinary angiotensinogen after 4 weeks of treatment relative to the baseline between canagliflozin intervention group and control group INCLUSION CRITERIA: ‐patients with stable type 2 diabetes ‐eGFR(Crteatinine)<= 60mL/min/1.73m2 ‐patients who are taking renin angiotensin system inhibitors (exclude intolerable or non‐adaptive) ‐older than 18 years ‐written consent